-->

Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesMay 14, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 14, 2009View HTMLDownload DOCDownload PDF
10-QQuarterly report which provides a continuing view of a company's financial positionMay 1, 2009View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventApr 30, 2009View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GApr 21, 2009View HTMLDownload DOCDownload PDF
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Apr 13, 2009View HTMLDownload DOCDownload PDFDownload XLS
ARSAn annual report to security holders.Apr 6, 2009View HTMLDownload DOCDownload PDF
DEFA14AAdditional proxy soliciting materials - definitiveApr 2, 2009View HTMLDownload DOCDownload PDFDownload XLS
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 2, 2009View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventApr 1, 2009View HTMLDownload DOCDownload PDFDownload XLS
CT ORDERConfidential treatment orderMar 27, 2009View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventMar 23, 2009View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesMar 17, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 13, 2009View HTMLDownload DOCDownload PDF
3Initial filing by director officer or owner of more than ten percent.Mar 11, 2009View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GMar 10, 2009View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Mar 10, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 9, 2009View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsMar 6, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 4, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 4, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 4, 2009View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 4, 2009View HTMLDownload DOCDownload PDF
10-KAnnual report which provides a comprehensive overview of the company for the past yearFeb 27, 2009View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesFeb 26, 2009View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-93

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information